• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cytori touts regenerative cell therapy data

October 24, 2016 By Sarah Faulkner

Cytori touts regenerative cell therapy dataCytori Therapeutics (NSDQ:CYTX) touted the publication of preclinical safety and efficacy data for its cell therapy treatment for combined radiation and thermal injury.

The San Diego-based company said the current healthcare system is ill-prepared to care for large numbers of patients that require simultaneous treatment and that patients with severe burns commonly suffer with prolonged pain and aggressive scarring. The company touts its autologous cell therapies as a cost-effective way to improve the quality and rate of wound healing, while reducing scarring.

Cytori’s cell therapy is derived from human adipose tissue, or fat, and is also known as adipose-derived regenerative cells. Because the regenerative cells come from the patient’s body, treatment with these cells avoid cell rejection and do not require immunosuppressive drugs. Previous studies have shown that the cells can promote angiogenesis – the creation of new blood vessels from pre-existing vessels. Preclinical studies also demonstrated that the regenerative cells are associated with wound healing, promoting the expression of extracellular matrix components and remodeling enzymes.

The study, published in the International Journal of Radiation Biology, evaluated local and intravenous administration of the cell therapy to burns that were compromised by exposure to marrow-damaging total body irradiation. Two weeks after treatment, the treated wounds had 3.5 times greater re-epitheliazation and a 67% increase in blood vessel density on average. The treated wounds also saw a 30% increase in collagen deposition. The therapy was well tolerated and no serious side effects were observed over the course of the study.

“These preclinical data support the clinical rationale for the investigational use of topical or intravenous administration of Cytori cell therapy in burn patients,” Dr. John Fraser, Cytori’s chief scientist, said in prepared remarks. “We are leveraging this data in a forthcoming U.S. FDA investigational device exemption (IDE) application for the RELIEF Phase I clinical trial to assess the safety and feasibility of the intravenously administered Cytori Cell Therapy as a novel thermal burn countermeasure.”

Filed Under: Featured, Preclinical Trials, Regenerative Medicine, Research & Development Tagged With: Cytori Therapeutics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS